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Abstract  43 
 44 
The β cell-enriched MAFA transcription factor plays a central role in regulating glucose-stimulated insulin 45 
secretion while also demonstrating oncogenic transformation potential in vitro. No disease-causing MAFA variants 46 
have been previously described. We investigated a large pedigree with autosomal dominant inheritance of diabetes 47 
mellitus or insulinomatosis, an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by 48 
multiple insulin-secreting neuroendocrine tumors of the pancreas. Using exome sequencing we identified a novel 49 
missense MAFA mutation (p.Ser64Phe, c.191C>T) segregating with both phenotypes of insulinomatosis and 50 
diabetes. This mutation was also found in a second unrelated family with the same clinical phenotype, while no 51 
germline or somatic MAFA mutations were identified in nine patients with sporadic insulinomatosis. In the two 52 
families, insulinomatosis presented more frequently in females (eight females/two males) and diabetes more often 53 
in males (12 males/four females). Four patients from the index family, including two homozygotes, had a history 54 
of congenital cataract and/or glaucoma. The p.Ser64Phe mutation was found to impair phosphorylation within the 55 
transactivation domain of MAFA, and profoundly increased MAFA protein stability under both high and low 56 
glucose concentrations in β cell lines. In addition, the transactivation potential of p.Ser64Phe MAFA in β cell lines 57 
was enhanced as compared with wild type MAFA. In summary, the p.Ser64Phe missense MAFA mutation leads 58 
to familial insulinomatosis or diabetes by impacting MAFA protein stability and transactivation ability. The human 59 
phenotypes associated with the p.Ser64Phe MAFA missense mutation reflect both the oncogenic capacity of 60 
MAFA and its key role in islet β cell activity.  61 
 62 
Significance statement  63 
 64 
We report the first instance of a disease-causing mutation in the β cell-enriched MAFA transcription factor. 65 
Strikingly, the missense p.Ser64Phe MAFA mutation was associated with either of two distinct phenotypes, 66 
multiple insulin-producing neuroendocrine tumors of the pancreas – a condition known as insulinomatosis – or 67 
diabetes mellitus, recapitulating the physiological properties of MAFA both as an oncogene and as a key islet β 68 
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cell transcription factor. The implication of MAFA in these human phenotypes will provide novel insights on how 69 
this transcription factor regulates human β cell activity as well as on the mechanisms of Maf-induced 70 
tumorigenesis. 71 
 72 
  73 
 4 
 
Introduction 74 
 75 
The MAFA (V-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog A) basic leucine zipper 76 
containing protein is unique among the many distinct islet-enriched transcription factors, as it plays a pivotal role 77 
in the regulation of insulin secretion in vivo while at the same time displaying oncogenic transformation potential 78 
in vitro (1-3). MAFA belongs to the family of large Maf transcription factors, also including MAFB, MAF, and 79 
NRL. MAFA and MAFB are both expressed in islet β cells, but only MAFA is required for their post-natal function 80 
(4-6), acting as transactivator of insulin and several genes involved with glucose-stimulated insulin secretion (1, 81 
7-9). The transformation potential of MAFA was shown by its ability to induce proliferation of quail neuroretina 82 
cells (2) and chicken embryo fibroblasts (3) when overexpressed in vitro. Notably, the related human MAF gene 83 
is upregulated in 50% of human multiple myelomas and 60% of angioimmunoblastic T-cell lymphomas (10, 11). 84 
In addition, recurrent translocations involving MAF, MAFB, and MAFA are identified in 5-10% of multiple 85 
myelomas (12-14), highlighting the significant role of these oncogenes in hematological malignancies. 86 
In this study, we aimed to determine the genetic etiology of insulinomatosis, a condition characterized by the 87 
occurrence of multicentric insulinomas, pancreatic neuroendocrine tumors with β cell-like features causing 88 
hyperinsulinemic hypoglycemia. Insulinomatosis usually occurs sporadically (15), although had also been 89 
described to occur in a familial setting in one single kindred where hyperinsulinemic hypoglycemia was 90 
paradoxically associated with a strong family history of diabetes mellitus (16). Due to the multicentric nature of 91 
the disease, insulinomatosis patients have a significantly higher chance of persistent or recurrent disease following 92 
conservative surgery compared to patients with a single sporadic insulinoma, and their management is often 93 
challenging (15). By sequencing the exomes of multiple affected individuals from a large autosomal dominant 94 
pedigree with insulinomatosis and diabetes, we identified a novel missense p.Ser64Phe (c.191C>T) mutation in 95 
the MAFA gene segregating with both phenotypes. Targeted sequencing in a second independent family with an 96 
identical clinical phenotype revealed the same MAFA mutation, while no pathogenic variants were found in a 97 
series of insulinomatosis patients with sporadic clinical presentation. Functional analysis demonstrated that the 98 
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p.Ser64Phe mutation not only significantly increased the stability of MAFA, whose levels were unaffected by 99 
variable glucose concentrations in β cell lines, but also enhanced its transactivation activity.  100 
 101 
Results 102 
 103 
Exome and targeted sequencing identify the p.Ser64Phe MAFA mutation. The study population consisted of 104 
an index family with autosomal dominant insulinomatosis and diabetes (Family 1; Figure 1A; 29 subjects, 17 105 
females), a second family with the same phenotype, whose case was previously clinically described (16) (Family 106 
2; Figure 1B; seven subjects, two females), and nine cases of sporadic insulinomatosis (eight females). All subjects 107 
were of white Caucasian ethnic background. 108 
Exome sequencing of subjects III/1, III/2, III/8, and IV/4 from Family 1 identified 59, 85, 80, and 84 novel 109 
heterozygous variants, respectively, annotated as missense, nonsense, frameshift, or splice site variants. Only one 110 
of these, MAFA p.Ser64Phe (c.191C>T; NM_201589.3), was shared by all four affected individuals (Table S1 and 111 
S2). This variant affects a highly conserved amino acid within the transactivation domain of MAFA, and has not 112 
been reported before (ExAC, GnomAD, ESP, dbSNP, and 1000 Genomes databases). In silico prediction 113 
supported a pathogenic role (Table S3). Testing for this MAFA missense variant in 25 additional members from 114 
Family 1 identified 14 further heterozygous individuals (18 in total) and two homozygotes (IV/2 and IV/5). Nine 115 
unaffected family members did not inherit the variant (Figure 1A). Seven of the 18 heterozygotes had 116 
insulinomatosis, 10 had diabetes, and one was clinically unaffected (IV/3, aged 35). No DNA was available from 117 
patient III/10, who was an obligate carrier of the MAFA variant (Figure 1A) and was known to have an impaired 118 
fasting glucose. 119 
Targeted sequencing of MAFA in Family 2 identified the same heterozygous p.Ser64Phe MAFA mutation in the 120 
proband (III/1, with insulinomatosis) and in four additional family members, one currently affected with 121 
insulinomatosis (III/3), one with diabetes (IV/1), and two who were not known to be affected (IV/2, aged 47 and 122 
IV/3, aged 41). The three deceased affected subjects in Family 2 – two with diabetes (II/2 and III/5) and one with 123 
insulinomatosis (II/1) – were obligate carriers (Figure 1B). Disease penetrance for both phenotypes 124 
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(insulinomatosis or diabetes) was 90%. Haplotype analysis within the two families suggested that the mutations 125 
had arisen on separate alleles (Figure S1), although a recombination event within a 364kb region encompassing 126 
MAFA could not be excluded. DNA sequence analysis of the nine sporadic insulinomatosis cases did not detect 127 
germline or somatic MAFA pathogenic variants. 128 
 129 
Individuals with the p.Ser64Phe MAFA mutation develop either hyperinsulinemic hypoglycemia or diabetes 130 
mellitus. In the two families we report, 10 subjects had hyperinsulinemic hypoglycemia secondary to 131 
insulinomatosis (Table S4), while 15 patients were diagnosed with diabetes mellitus (Table S5). Most subjects 132 
with hyperinsulinemic hypoglycemia were females (male-to-female patient ratio was 1:4), and the mean age at 133 
diagnosis was 39.4±13.1 years. There was no history of early-onset hypoglycemia suggestive of congenital 134 
hyperinsulinism. In four out of six patients that underwent imaging investigations, multicentric pancreatic 135 
neuroendocrine tumors (ranging in size between 0.4 and 1.1cm) were shown, while local or distant metastases 136 
were not observed. In one patient with hyperinsulinemic hypoglycemia from Family 2 (III/1) who was diagnosed 137 
before cross-sectional imaging investigations became available, a 5mm insulinoma was found in the resected 138 
sample following pancreatic surgery (16). Overall, six patients underwent surgery, with persistent or recurrent 139 
disease in all cases, and four patients underwent more than one operation. The subjects with persistent or recurrent 140 
disease, and those who did not undergo pancreatic surgery, were managed with medical treatment with generally 141 
poor results and recurrent symptomatic hypoglycemia.  142 
Most patients diagnosed with diabetes or impaired fasting glucose were males (male-to-female ratio was 3:1), and 143 
the mean age at diagnosis was 38.4±16.5 years. The mean BMI of patients with diabetes with available data was 144 
25±3kg/m2. There were no other clinical features of insulin resistance, no history of diabetic ketoacidosis and islet 145 
auto-antibodies were negative, configuring a phenotype resembling maturity-onset diabetes of the young (MODY) 146 
(17). Diabetes was managed with diet or oral medications (i.e. metformin and/or sulphonylureas) in most cases, 147 
with current HbA1c levels ranging between 37 and 74 mmol/mol (5.5-8.9%). There was no history of clinically 148 
significant micro- or macrovascular complications. Among the subjects with diabetes, two homozygous patients 149 
from Family 1 born to consanguineous parents presented with congenital glaucoma (IV/2) and congenital cataract 150 
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(IV/5), while two heterozygous subjects (III/16 and III/20) from the same family had congenital cataract 151 
associated, in one of these (III/16), with congenital glaucoma. There was no history of congenital eye disorders in 152 
Family 2.  153 
Insulinomatosis and diabetes seemed to be mutually exclusive diagnoses in most patients. However, one subject 154 
from Family 2 (III/3) might have developed the two phenotypes in a sequential manner. This subject was diagnosed 155 
with gestational diabetes at the age of 27. After giving birth, she had impaired glucose tolerance and was treated 156 
with sulphonylureas between age 33 and 35. An oral glucose tolerance test whilst off treatment at the age of 39 157 
years was reported normal. This patient started to show symptoms of hypoglycemia at the age of 55, and was later 158 
diagnosed with hyperinsulinemic hypoglycemia and multiple pancreatic neuroendocrine tumors on 18F-DOPA 159 
PET imaging (Figure 2A-B).  160 
The three unaffected heterozygotes had normal HbA1c and fasting glucose levels in the absence of clinical 161 
symptoms of hypoglycemia. Subject IV/2 (Family 2) was prospectively diagnosed with impaired glucose tolerance 162 
following an oral glucose tolerance test (oGTT) (Figure S2). The insulinogenic index calculated for this patient on 163 
the basis of baseline and 30 minutes glucose and insulin levels was 37.6pmol/mmol, with a normal HOMA-IR of 164 
1.7, in keeping with impaired insulin secretion. An oGTT in one of the unaffected heterozygotes from Family 1 165 
(IV/3) showed normal glucose tolerance, with 120 minutes glucose levels of 5.4mmol/L.  166 
 167 
Hyperinsulinemic hypoglycemia in patients with the p.Ser64Phe MAFA mutation is due to multiple 168 
insulinomas. In the subjects with hyperinsulinemic hypoglycemia that underwent surgery, histopathology showed 169 
the presence of small (microadenomas, <5mm) and larger (macrotumors, >5mm) multifocal well-differentiated 170 
neuroendocrine tumors (Ki-67 <2%) with a trabecular tissue architecture (Figure 2C-D). The number of lesions 171 
was variable, depending on the type of surgery and extension of sampling. Over 100 lesions were identified in a 172 
patient from Family 2 (III/1) whose surgical specimen was fully sampled (15). Islets with β cell hyperplasia 173 
transforming into microadenomas were not observed. None of the tumors exceeded 2cm in size. All tumors 174 
expressed insulin, while immunostaining for the other pancreatic hormones was negative. MAFA immunostaining 175 
revealed a diffuse positivity in one case from Family 1 (III/19), which was less intense as compared to the 176 
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neighboring normal islets (Figure 2E), and a patchy positivity in the index case from Family 2 (III/1). 177 
Notwithstanding the limitations due to the small number of tissue samples available for further analysis, the MAFA 178 
staining intensity did not appear to be different in MAFA mutation-positive tumor cells compared with MAFA 179 
mutation-negative sporadic insulinomatosis or sporadic insulinomas (Table S6).  180 
 181 
The p.Ser64Phe MAFA mutation affects MAFA protein stability and transactivation activity. Ser64 is found 182 
within the N-terminal transactivation domain of MAFA (Figure 3A). The neighboring Ser65 residue was 183 
previously shown to act as a priming phosphorylation site, as phosphorylation at Ser65 enables glycogen synthase 184 
kinase-3 (GSK3) to phosphorylate Ser61, Thr57, Thr53, and Ser49 in a sequential manner (Figure 3A) (18, 19). 185 
We found the mobility of the p.Ser64Phe mutant protein to be indistinguishable from the kinase priming defective 186 
mutant, p.Ser65Ala (Figure 3B), suggesting that the substitution of serine with a phenylalanine at residue 64 187 
prevents phosphorylation at the priming Ser65 site, and the subsequent GSK3-mediated phosphorylation within 188 
the transactivation domain of MAFA. However, both p.Ser65Ala and p.Ser64Phe MAFA were still heavily 189 
phosphorylated proteins at the many other phosphorylation sites (Figure 3A), as shown by the ability of an 190 
endogenous phosphatase(s) to alter protein mobility when incubated in the presence of NaCl, but not the 191 
phosphatase inhibitor, sodium orthovanadate (Na3VO4) (Figure 3B) (20).  192 
The p.Ser64Phe mutation was found to have a profound effect on MAFA turnover. The stability of the mutant 193 
protein was dramatically increased in both the human EndoC-βH1 β cell line (Figure 4) and MIN6 cells (Figure 194 
S3) in the presence of cycloheximide, a protein synthesis inhibitor. Normally, MAFA is highly unstable in β cells 195 
at low, non-stimulating glucose concentrations, while its stability is enhanced in the presence of high glucose 196 
concentrations (19). However, the p.Ser64Phe mutant was stable and abundant regardless of glucose levels (Figure 197 
4A-B and S3). No significant difference was observed between transfected wild type (WT) and mutant MAFA 198 
mRNA levels (Figure 4C), confirming the post-transcriptional nature of the effect observed on protein turnover.  199 
We next tested whether the p.Ser64Phe mutation affected stimulation of an insulin enhancer/promoter-driven 200 
reporter. There appeared to be no difference in the transactivation capacity in HeLa cells, as no predictable change 201 
in the specific activity pattern was observed between constructs (Figure S4). Notably, there was a non-linear 202 
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relationship in WT or mutant construct activity in relation to increasing amounts of protein, presumably due to the 203 
inability to properly phosphorylate the protein at its many phosphorylation sites (21) under these conditions. To 204 
focus on the impact of the p.Ser64Phe mutation on transactivation activity, chimeric proteins containing the N-205 
terminal transactivation domain fused to the yeast Gal4 DNA-binding domain were produced. When analyzed in 206 
Gal4 binding site-driven reporter assays, the Gal4-Ser64Phe MAFA chimera was found to be more active than the 207 
WT chimera in INS-1 β cells compared with HeLa cells (Figure S5A). Importantly, the chimeric WT and 208 
p.Ser64Phe mutant proteins were expressed at equal levels (Figure S5B), as they both lack the lysine residues 209 
targeted for ubiquitination in the C-terminal DNA-binding/dimerization region (20). Collectively, these results 210 
suggest that the activity of p.Ser64Phe MAFA would be enhanced due to both increased transactivation capacity 211 
and increased protein stability. 212 
 213 
Discussion 214 
 215 
We report the first disease-causing mutation in the β cell-enriched MAFA transcription factor. A p.Ser64Phe 216 
MAFA missense mutation was identified in 25 individuals from two unrelated families who were affected with 217 
either insulinomatosis or non-insulin dependent diabetes resembling maturity-onset diabetes of the young 218 
(MODY). Our results are in keeping with previous evidence highlighting the role of MAFA in glucose-stimulated 219 
insulin secretion, and at the same time suggest that the p.Ser64Phe missense mutation can allow the oncogenic 220 
potential of MAFA – previously described in different cell contexts – to be manifested in the β cell. 221 
MAFA regulates the expression of insulin and several genes involved in glucose-stimulated insulin secretion (1, 222 
7-9), and serves as a glucose “barometer”, since its stability and activity in β cells are increased under high glucose 223 
stimulating conditions and repressed in the presence of low glucose (19). The p.Ser64Phe mutation affects a highly 224 
conserved residue within the N-terminal transactivation domain of MAFA, neighboring the priming kinase Ser65 225 
phosphorylation site. Significantly, no missense variants have been reported in publicly available databases at any 226 
of the N-terminal residues in MAFA subjected to sequential phosphorylation (Ser49, Thr53, Thr57, Ser61, or 227 
Ser65) or at immediately neighboring residues, including Ser64. The identical mobility of the p.Ser64Phe and 228 
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p.Ser65Ala mutants strongly suggests that the p.Ser64Phe mutation impairs phosphorylation at Ser65, and the 229 
consequent GSK3-mediated phosphorylation within the transactivation domain of MAFA. These phosphorylation 230 
events in the N-terminal transactivation domain of MAFA induce both transactivation capacity (22) and protein 231 
degradation (18-20), the latter resulting from ubiquitination in the C-terminal domain. Consistently with the 232 
impaired phosphorylation within the transactivation domain, the p.Ser64Phe MAFA protein was strikingly more 233 
stable compared to WT MAFA, and its turnover was unaffected by different glucose concentrations in β cell lines. 234 
Moreover, the activity of the Gal4-Ser64Phe chimeric protein was found to be greater than Gal4-WT MAFA in 235 
INS-1 β cells compared with non-β HeLa cells. Previous studies have shown that the transactivation activity of 236 
the Gal4-Ser65Ala protein was reduced in non-β cells (20), while the activity of chimeric proteins lacking the 237 
priming phosphorylation and the GSK3 phosphorylation sites was found to be enhanced in an insulinoma cell line 238 
(19). This suggests that phosphorylation within the transactivation domain may affect MAFA function in a cell 239 
context dependent way, likely through interactions with other β cell-specific transcription factors and/or co-240 
regulators. Together, our results suggest that the p.Ser64Phe mutation increases the activity of endogenous MAFA 241 
in β cells by impacting both protein stability and transactivation potential.   242 
The family of Maf transcription factors derives its name from v-maf, which is transduced as a viral oncogene 243 
capable of inducing muscoloaponeurotic fibrosarcoma in chickens (23, 24).  MAF, MAFB, and MAFA all display 244 
oncogenic activity (25), with MAFA having the greatest transformation potential in vitro (3). Notably, only high 245 
copy number Maf expressing transgenic mice develop T-cell lymphomas (10), and the translocations occurring in 246 
human multiple myelomas (12, 13) determine the ectopic overexpression of large Maf proteins, suggesting that 247 
cell transformation is dependent on the overexpression of these transcription factors. Both the higher protein levels 248 
and the increased activity of the p.Ser64Phe mutant are predicted to induce the expression of genes involved with 249 
cell cycle regulation, including CCND2, a known target of MAFA (6) and key regulator of β cell proliferation 250 
(26), presumably causing β cell transformation and occurrence of insulinomatosis. Our data also suggest that the 251 
p.Ser64Phe mutation alters the tight regulation of MAFA stability in response to changes in glucose concentration. 252 
The lack of up-regulation of MAFA in response to hyperglycemia is expected to impair glucose-stimulated insulin 253 
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secretion, consistent with the results of the oGTT in one of the prospectively identified mutation carriers, and this 254 
mechanism presumably underlies the diabetes phenotype. 255 
The mechanisms explaining how the same gene mutation can lead to diabetes or insulinomatosis remains to be 256 
fully elucidated, and in vivo models will have to be developed to further investigate the effects of the p.Ser64Phe 257 
mutation. A similarly paradoxical phenotype has been described for mutations in the transcription factor HNF4A 258 
(27-29) and the potassium channel gene ABCC8 (30), where diabetes can be preceded, in some patients, by 259 
transient congenital hyperinsulinism. Insulinomatosis is, however, a very different disease, as it only manifests in 260 
adults, and is a neoplastic condition defined by the occurrence of multicentric insulin-producing neuroendocrine 261 
tumors, as opposed to congenital hyperinsulinism, characterized by islet cell hypertrophy in the absence of 262 
neoplastic changes (31). Although we cannot exclude the possibility that insulinomatosis patients had diabetes 263 
prior to developing symptoms of hyperinsulinemic hypoglycemia, in most cases the two phenotypes seemed 264 
mutually exclusive, and inter-individual factors might determine the development of either insulinomatosis or 265 
diabetes. Interestingly, in our two families, patients with insulinomatosis were mostly females and those with 266 
diabetes were more frequently males. The reasons for this gender difference are not known, although sporadic 267 
insulinomas also occur more frequently in females, with a male-to-female ratio of 1:1.4 (32). Treatment with 268 
estrogens has been shown to promote proliferation (33) and increase insulin release in human β cells and human 269 
insulinomas in vitro (34, 35). Moreover, the expansion of β cell mass observed during pregnancy is thought to be 270 
induced by prolactin and placental lactogen signaling mediated by the prolactin receptor (PRLR) (36-38). Notably, 271 
Prlr was significantly downregulated in Mafa knockout islets and in MIN6 β cells following siRNA-mediated 272 
knockdown of Mafa (39), and, in the same study, the Prlr promoter was shown to be directly activated by MAFA 273 
in luciferase reporter assays. Estrogens and prolactin could potentially promote β cell proliferation, predisposing 274 
female carriers of the p.Ser64Phe MAFA mutation to develop insulinomatosis – remarkably all insulinomatosis 275 
female patients manifested symptoms of the disease after puberty and most of them displayed the first 276 
hypoglycemic symptoms either during (16) or after pregnancy – although we cannot exclude that additional factors 277 
might influence the development of either phenotype. 278 
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Four subjects, including the only two homozygotes, presented with congenital cataract and/or glaucoma. MAFA is 279 
expressed in the developing lens (40), and mutations in the MAF gene have been previously linked with congenital 280 
cataract and disorders of the anterior segment (41), supporting a role for the p.Ser64Phe MAFA mutation in the 281 
pathogenesis of the ocular phenotype. Moreover, no MAFA mutations, either at the germline or somatic level, were 282 
detected in insulinomatosis patients with sporadic clinical presentation, implying that MAFA-independent 283 
mechanisms are involved in the pathogenesis of sporadic insulinomatosis. Similarly, no MAFA pathogenic variants 284 
were previously identified in a series of patients with genetically undetermined MODY (42), indicating that MAFA 285 
mutations are specifically linked to the association of diabetes and familial insulinomatosis. 286 
In conclusion, we identified a MAFA missense mutation as the cause of a dual familial condition of diabetes 287 
mellitus or hyperinsulinemic hypoglycemia secondary to insulinomatosis. Our data show that the p.Ser64Phe 288 
mutation impairs phosphorylation in the transactivation domain of MAFA, leading to significantly enhanced 289 
protein stability and activity in β cell lines. The implication of a MAFA mutation in human disease is expected to 290 
provide further insights on the role of this transcription factor in the β cell.  291 
 292 
Materials and Methods 293 
 294 
Patient samples. We recruited two families with autosomal dominant insulinomatosis and diabetes mellitus (36 295 
subjects, 19 females), and nine patients with sporadic insulinomatosis (eight females; clinical features are 296 
summarized in Table S7). All patients and family members agreed to take part in our multicenter study approved 297 
by the National Research Ethics Service Committee East of England – Cambridge East by providing signed 298 
informed consent. 299 
 300 
Genetic analyses. Genomic DNA was extracted from peripheral blood leukocytes, saliva, or formalin-fixed 301 
archival tissue using commercially available kits (further details are provided in the Supporting Information). 302 
Exome sequencing was performed in four individuals affected with insulinomatosis from Family 1 (III/1, III/2, 303 
III/8, and IV/4) using the Agilent’s SureSelect Human All Exon Kit (v5) (Agilent, Santa Clara, CA, USA) with 304 
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sequencing on an Illumina HiSeq2500 system (Illumina, San Diego, CA, USA). Sequencing metrics for the four 305 
samples are reported in Table S8. We assumed a rare autosomal dominant model of inheritance to filter novel (not 306 
previously reported in the ExAC, ESP, dbSNP, and 1000 Genomes databases) heterozygous variants annotated as 307 
missense, nonsense, frameshift, or splice site variants. The effect of the identified MAFA missense variant was 308 
investigated in silico using SIFT (http://sift.jcvi.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), and 309 
Align GVCD (http://agvgd.iarc.fr/agvgd_input.php/) prediction tools. Sanger sequencing was used for validation 310 
and co-segregation studies in Family 1, and for the sequencing of the whole coding sequence of MAFA in Family 311 
2 and in sporadic insulinomatosis patients. Primer sequences are provided in Table S9. Methods for haplotype 312 
analysis are reported in the Supporting Information.  313 
 314 
Pathological assessment and MAFA immunohistochemistry. Immunohistochemistry on archival pancreatic 315 
tissue for neuroendocrine markers, Ki-67, and pancreatic hormones (insulin, gastrin, glucagon, pancreatic 316 
polypeptide) was performed as previously described (43). MAFA expression was assessed using 317 
immunohistochemistry in two familial insulinomatosis samples, eight sporadic insulinomatosis, and six sporadic 318 
insulinoma controls and classified as negative, weak, moderate, strong, or patchy. All cases were reviewed by an 319 
experienced endocrine pathologist (G.K.).   320 
 321 
Protein mobility analysis. Details for plasmid preparation are reported in the Supporting Information. Nuclear 322 
extracts of WT, p.Ser64Phe, and p.Ser65Ala MAFA-transfected HeLa cells were incubated at 37°C for 40 or 80 323 
minutes in the presence of sodium orthovanadate (Na
3
VO
4
, 10mM) or NaCl (10mM). The samples were analyzed 324 
by SDS polyacrylamide gel electrophoresis and immunoblotting with an anti-MAFA antibody (Bethyl 325 
Laboratories, Montgomery, TX, USA; A300-611A).  326 
 327 
Luciferase assays. The rat insulin II enhancer/promoter driven -238 firefly luciferase plasmid (Promega, Madison, 328 
WI, USA) was transfected in HeLa cells along with pCMV4-MAFA and phRL-TK (Promega) using the 329 
Lipofectamine protocol (Life Technologies). Gal4-MAFA(1-167) was transfected in HeLa and INS-1 832/13 cells 330 
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along with (Gal4)5E1bLuc and phRL-TK. Cellular extracts were collected 48 hours post-transfection, and the 331 
Dual-Luciferase Reporter Assay (Promega) was performed according to the manufacturer's directions. MAFA 332 
protein levels were normalized to endogenous β-actin by immunoblotting with anti-MAFA (Bethyl Laboratories; 333 
A300-611A) and anti-β-actin (Cell Signaling, Danvers, MA, USA; 4967S) antibodies.  334 
 335 
Cycloheximide chase experiments. WT and p.Ser64Phe MAFA-Myc were introduced into EndoC-βH1 cells (44) 336 
using the Amaxa Nucleofector 2 (Program G-016; Lonza Walkersville, MD, USA). The medium was changed 48 337 
hours following nucleofection to either 1.1 or 15.5mM glucose for 12 hours, and cycloheximide (Sigma, St. Louis, 338 
MO, USA) was then added at a concentration of 25μg/mL for the time indicated. Nuclear extracts were prepared 339 
for immunoblotting and probed with anti-Myc (Roche, Penzberg, Germany; clone 9E10) and anti-β-actin (Cell 340 
Signaling; 4967S) antibodies. RNA from EndoC-βH1 cells was collected 72 hours post-nucleofection using the 341 
Trizol reagent (Life Technologies), and the iScript cDNA synthesis kit (Biorad, Hercules, CA, USA) was used for 342 
cDNA synthesis. The qPCR reactions were performed with MAFA-Myc, MAFA (endogenous), and GAPDH gene 343 
primers on a LightCycler 480 II (Roche), and analyzed by the ∆∆CT method. Cycloheximide chase experiments 344 
were also performed in MIN6 cells transfected with WT and p.Ser64Phe MAFA-Myc using the Lipofectamine 345 
protocol (Life Technologies). Each experiment was repeated at least three times. 346 
 347 
Statistical analysis. Parametric data are presented as mean ± standard deviation (SD). Normal distribution was 348 
assessed using the Shapiro-Wilk test. Experimental data (luciferase and qPCR experiments) were analyzed through 349 
the Student’s t-test using the software Prism v5 (GraphPad Software Inc, La Jolla, CA, USA). Cycloheximide 350 
chase experiments were analyzed using a one-phase decay equation, and the degradation speed (K) was compared 351 
between the mutant and the WT protein using the extra sum-of-squares F test. Significance was set for P values 352 
<0.05.  353 
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Figure Legends 472 
 473 
Figure 1. Family trees of the two families with insulinomatosis and diabetes mellitus. Different colors mark 474 
the MAFA genotypes. Unmarked subjects were not tested. A simplified version of the family tree was used for 475 
Family 1 to improve readability.  476 
 477 
Figure 2. Features of MAFA mutation-positive insulinomatosis. A-B. 
18
F-DOPA PET in a patient with MAFA 478 
mutation-positive insulinomatosis (Family 2, subject III/3) showing two pancreatic neuroendocrine tumors (red 479 
arrow) (A, tail; B, body of the pancreas). C. Chromogranin A immunohistochemistry in subject III/19 (Family 1) 480 
shows a macrotumor (>5mm) (asterisk) and multiple small (microadenomas, <5mm) neuroendocrine tumors 481 
(black arrows). D. H&E staining showing the trabecular pattern of MAFA mutation-positive insulinomas. E. 482 
Immunostaining shows diffuse MAFA expression in the tumor, at lower levels as compared to the neighboring 483 
normal islets strongly expressing MAFA (insert). 484 
 485 
Figure 3. The mobility of p.Ser64Phe (S64F) MAFA is indistinguishable from the p.Ser65Ala (S65A) kinase 486 
mutant. A) Schematic of MAFA showing sites of phosphorylation (red dots) within the transactivation, DNA-487 
binding (basic), and dimerization region (leucine zipper, L-Zip). B) Wild type (WT) and mutant MAFA transfected 488 
HeLa nuclear extracts were incubated at 37°C for 40 or 80 minutes (40’ or 80’) in the presence of the phosphatase 489 
inhibitor, sodium orthovanadate (Na
3
VO
4, 10mM), or NaCl (10mM). The arrowheads denote the location of fully 490 
phosphorylated MAFA (F-P, blue), the form lacking Ser65 and GSK3-mediated phosphorylation (Un-P, red), and 491 
the completely dephosphorylated protein produced by incubating in the presence of NaCl (De-P, white).  492 
 493 
Figure 4. The p.Ser64Phe (S64F) mutation greatly stabilizes MAFA in human EndoC-βH1 cells grown in 494 
1.1 or 15.5mM glucose. A) EndoC-βH1 cells were transfected with wild type (WT) and p.Ser64Phe (S64F) 495 
MAFA-Myc and, after 48 hours, incubated with medium containing 1.1mM or 15.5mM glucose for an additional 496 
12 hours. The transfected cells were then incubated with 25μg/mL cycloheximide (CHX) for the indicated time. 497 
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Transfected MAFA-Myc and endogenous β-actin protein levels were determined by immunoblotting (IB) using 498 
anti-Myc and anti-β-actin antibodies, respectively. B) The Myc protein band intensity was measured in the 499 
15.5mM glucose sample, normalized to β-actin, and plotted as a percentage of the initial band intensity. C) No 500 
significant difference was found between WT and p.Ser64Phe (S64F) MAFA mRNA levels in transfected cells 501 
grown in 1.1mM glucose. Endogenous MAFA mRNA levels also did not change under these conditions. Student’s 502 
two-tailed t-test. n.s., not significant. n = 3. Error bars represent SEM. 503 
 504 
